Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Prothena Corporation plcNASDAQ: PRTA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $6.92M fell 36.8% year over year, behind the -24.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +6.3% a year.

Context

  • Stock-based compensation amounted to 388.7% of revenue in FY2025, up 354.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -36.8% toward the trailing-twelve-month pace of -24.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.92M-2.2% QoQ
Last fiscal yearDec 2025
$37.64M-18.1% YoY
LTMMar 2026
$33.61M-24.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.8%——
1 year-18.1%——
3-year CAGR+6.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
37.64M USD
Year-over-year change
-18.1%
4-year CAGR
+11.2%

Stock-Based Compensation vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.5% is the 6th highest of 10, against a peer median of -21.9%.
  • Stock-based compensation amounts to 58.0% of revenue for PRTA, versus a peer median of 75.0%.
PRTA Competitors
Stock-Based Compensation for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PMNProMIS Neurosciences, Inc.LTM Jun 2026$857.38M USD+71257.3%+9.4%—
BIIBBiogen Inc.LTM Jun 2026$134.9M USD-55.6%+4.6%1.4%
DNLIDenali Therapeutics Inc.LTM Jun 2026$69.95M USD+39.2%-0.1%1941.0%
PRTAProthena Corporation plcLTM Mar 2026$33.61M USD-24.5%+6.3%58.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M USD-33.3%+53.3%—
ANNXAnnexon, Inc.LTM Mar 2026$15.5M USD-21.9%-3.9%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$10.6M USD+15.1%-14.3%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9.77M USD+1.5%+47.6%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.83M USD-42.1%-16.4%—
Peer median (excluding PRTA) —-21.9%+2.3%75.0%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.